The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin™ radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma
Kaminski, M. S., Zasadny, K. R., Francis, I. R., Fenner, M. C., Ross, C. W., Milik, A. W., Estes, J., Tuck, M., Regan, D., Fisher, S., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.7.1974 · Cited by 396 · cited 1×
“The volatile nature of iodine also poses an inhalation hazard to staff and dehalogenation of I with accumulation of free iodine in the thyroid poses a risk of hypothyroidism, though this can be reduced if an adequate thyroid blocking regime is followed [3].”
Background
Cited by
Ligand-targeted therapeutics in anticancer therapy
Allen, T. M. (2002) · Nature Reviews Cancer · doi:10.1038/nrc903 · Cited by 1,647
Witzig, T. E., Flinn, I. W., Gordon, L. I., Emmanouilides, C., Czuczman, M. S., Saleh, M. N., Cripe, L., Wiseman, G., Olejnik, T., Multani, P. S., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.11.017 · Cited by 651
Self-citationNanotheranostics and image-guided drug delivery: current concepts and future directions
Lammers, T., Kiessling, F., Hennink, W. E., & Storm, G. (2010) · Molecular Pharmaceutics · doi:10.1021/mp100228v · Cited by 397
Witzig, T. E., White, C. A., Gordon, L. I., Wiseman, G. A., Emmanouilides, C., Murray, J. L., Lister, J., & Multani, P. S. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.08.043 · Cited by 289
Self-citationDrug delivery vehicles on a nano-engineering perspective
Felice, B., Prabhakaran, M. P., Rodríguez, A. P., & Ramakrishna, S. (2014) · Materials Science and Engineering: C · doi:10.1016/j.msec.2014.04.049 · Cited by 253
Metadata
- Authors
- Wiseman, G. A., White, C. A., Sparks, R. B., Erwin, W. D., Podoloff, D. A., Lamonica, D., Bartlett, N. L., Anthony Parker, J., Dunn, W. L., Spies, S. M., Belanger, R., Witzig, T. E., & Leigh, B. R.
- Venue
- Critical Reviews in Oncology/Hematology
- Publisher
- Elsevier BV
- Published
- 2001-08
- Volume
- 39
- Issue
- 1-2
- Pages
- 181-194
- ISSN
- 1040-8428 (ISSN-L)
- OpenAlex
- W2054823183
- Cited by
- 183
- References
- 1
- FWCI
- 12.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin™ radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. https://app.cochat.ai/papers/10.1016/s1040-8428(01)00107-x
- The paper
- Wiseman, G. A., White, C. A., Sparks, R. B., Erwin, W. D., Podoloff, D. A., Lamonica, D., Bartlett, N. L., Anthony Parker, J., Dunn, W. L., Spies, S. M., Belanger, R., Witzig, T. E., & Leigh, B. R. (2001). Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin™ radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Critical Reviews in Oncology/Hematology. https://doi.org/10.1016/s1040-8428(01)00107-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.